Comparing calcium and vitamin D with Jarlsberg cheese for osteoporosis prevention
The Effect on Bone Marker and Body Mineral Density (BMD) of Daily Jarlsberg Cheese Intake in Risk Patient for Osteoporosis
This study is testing if adding Jarlsberg cheese to daily calcium and vitamin D can help improve bone health in post-menopausal women and men over 55 with low bone density.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 55 Years to 85 Years |
| Sex | All |
| Sponsor | Meddoc Academic / other |
| Locations | 1 site (Skjetten, Akershus) |
| Trial ID | NCT05787808 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effects of daily intake of calcium and vitamin D, with and without the addition of Jarlsberg cheese, on bone mineral density (BMD) and bone markers in patients with osteopenia. The study will involve post-menopausal women and men over 55 years of age, who will be randomly assigned to receive either the cheese or a control treatment. The trial will be conducted as a randomized, single-blinded multicenter study in Norway, focusing on changes in BMD and other bone health indicators over the treatment period.
Who should consider this trial
Good fit: Ideal candidates for this study are post-menopausal women and men over 55 years of age diagnosed with osteopenia.
Not a fit: Patients with eating disorders, gastrointestinal disorders, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel dietary approach to improve bone health and prevent osteoporosis in at-risk populations.
How similar studies have performed: While dietary interventions for bone health have been explored, the specific combination of Jarlsberg cheese with calcium and vitamin D in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Osteopeni patients (OP) of both genders above 55 years of age. OPs are defined as patients with T-score below 0.0 but larger than -2.5. Exclusion Criteria: * • Eating disorder * Known gastrointestinal disorder. * Abnormal liver or kidney function. * Diabetes mellitus type I. * Diabetes type II without sufficient control. * Suffering from verified cancer. * Under systemic treatment with corticosteroids or other immunosuppressive drugs the last 3 weeks before start of the trial treatment. * Under active antiresorptive treatment or anabolic treatment. * Participating in another clinical trial with pharmaceuticals the last six weeks before start of this trial treatment. * Known milk product allergy. * Not able to understand information. * Do not want or not able to give written consent to participate in the study.
Where this trial is running
Skjetten, Akershus
- Meddoc — Skjetten, Akershus, Norway (Recruiting)
Study contacts
- Study coordinator: Stig E Larsen, PhD
- Email: sl@meddoc.no
- Phone: +47 41326325
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.